Cargando…

Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells

Long non-coding RNAs (lncRNAs) can play significant regulatory roles in cells that affect the development and acquired drug resistance of lung cancer. Herein, we report that lncRNA linc00665 is significantly upregulated in non-small cell lung cancer (NSCLC) tissues compared with adjacent normal tiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Daolu, Feng, Wenyan, Zhuang, Yu, Liu, Junxia, Feng, Zhenqing, Xu, Tianwei, Wang, Wei, Zhu, Yefei, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887328/
https://www.ncbi.nlm.nih.gov/pubmed/33664990
http://dx.doi.org/10.1016/j.omtn.2021.01.013
_version_ 1783651958728425472
author Yang, Daolu
Feng, Wenyan
Zhuang, Yu
Liu, Junxia
Feng, Zhenqing
Xu, Tianwei
Wang, Wei
Zhu, Yefei
Wang, Zhaoxia
author_facet Yang, Daolu
Feng, Wenyan
Zhuang, Yu
Liu, Junxia
Feng, Zhenqing
Xu, Tianwei
Wang, Wei
Zhu, Yefei
Wang, Zhaoxia
author_sort Yang, Daolu
collection PubMed
description Long non-coding RNAs (lncRNAs) can play significant regulatory roles in cells that affect the development and acquired drug resistance of lung cancer. Herein, we report that lncRNA linc00665 is significantly upregulated in non-small cell lung cancer (NSCLC) tissues compared with adjacent normal tissues. linc00665 affects the sensitivity of NSCLC cells to the chemotherapy drug cisplatin (DDP), making it a potential target for the treatment of NSCLC. Functional experiments showed that linc00665 enhanced the proliferation and migration of NSCLC cells in vivo and in vitro, and knocking down linc00665 could enhance the drug sensitivity of NSCLC cells to DDP. Further work revealed that linc00665 could recruit enhancer of zeste homolog 2 (EZH2) to the promoter region of cyclin-dependent kinase inhibitor 1C (CDKN1C) to inhibit its transcription and thus carry out its tumorigenic role. In conclusion, our study elucidated the carcinogenic role of the linc00665-EZH2-CDKN1C axis in NSCLC tumors and its ability to influence the sensitivity of these tumors to DDP. These results suggest that linc00665 may be a potential diagnostic marker and therapeutic target in NSCLC, and they also provide a new direction for the development of clinical reversal methods for acquired drug resistance in patients with NSCLC.
format Online
Article
Text
id pubmed-7887328
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-78873282021-03-03 Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells Yang, Daolu Feng, Wenyan Zhuang, Yu Liu, Junxia Feng, Zhenqing Xu, Tianwei Wang, Wei Zhu, Yefei Wang, Zhaoxia Mol Ther Nucleic Acids Original Article Long non-coding RNAs (lncRNAs) can play significant regulatory roles in cells that affect the development and acquired drug resistance of lung cancer. Herein, we report that lncRNA linc00665 is significantly upregulated in non-small cell lung cancer (NSCLC) tissues compared with adjacent normal tissues. linc00665 affects the sensitivity of NSCLC cells to the chemotherapy drug cisplatin (DDP), making it a potential target for the treatment of NSCLC. Functional experiments showed that linc00665 enhanced the proliferation and migration of NSCLC cells in vivo and in vitro, and knocking down linc00665 could enhance the drug sensitivity of NSCLC cells to DDP. Further work revealed that linc00665 could recruit enhancer of zeste homolog 2 (EZH2) to the promoter region of cyclin-dependent kinase inhibitor 1C (CDKN1C) to inhibit its transcription and thus carry out its tumorigenic role. In conclusion, our study elucidated the carcinogenic role of the linc00665-EZH2-CDKN1C axis in NSCLC tumors and its ability to influence the sensitivity of these tumors to DDP. These results suggest that linc00665 may be a potential diagnostic marker and therapeutic target in NSCLC, and they also provide a new direction for the development of clinical reversal methods for acquired drug resistance in patients with NSCLC. American Society of Gene & Cell Therapy 2021-01-20 /pmc/articles/PMC7887328/ /pubmed/33664990 http://dx.doi.org/10.1016/j.omtn.2021.01.013 Text en © 2021 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Yang, Daolu
Feng, Wenyan
Zhuang, Yu
Liu, Junxia
Feng, Zhenqing
Xu, Tianwei
Wang, Wei
Zhu, Yefei
Wang, Zhaoxia
Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
title Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
title_full Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
title_fullStr Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
title_full_unstemmed Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
title_short Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
title_sort long non-coding rna linc00665 inhibits cdkn1c expression by binding to ezh2 and affects cisplatin sensitivity of nsclc cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887328/
https://www.ncbi.nlm.nih.gov/pubmed/33664990
http://dx.doi.org/10.1016/j.omtn.2021.01.013
work_keys_str_mv AT yangdaolu longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT fengwenyan longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT zhuangyu longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT liujunxia longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT fengzhenqing longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT xutianwei longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT wangwei longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT zhuyefei longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells
AT wangzhaoxia longnoncodingrnalinc00665inhibitscdkn1cexpressionbybindingtoezh2andaffectscisplatinsensitivityofnsclccells